|
|
 |
|
Viewing report
|
|
|
|
U.S. Sexual Dysfunction Medication Markets
Frost & Sullivan, Sep 2003
Increasing Incidence of Sexual Dysfunction Spurs Demand
An increasing dependence on medications that result in side effects of sexual dysfunction, growth in the baby boomer population, as well as in other comorbid groups such as cardiovascular, diabetes, and depression patients have greatly expanded the U.S. sexual dysfunction medication markets. These numbers continue to rise in the United States, setting the stage for higher demand and steady revenues. In addition, the small number of market participants has kept competition to a minimum in this lifestyle medication market.
This new research service presents a comprehensive discussion on current and emerging medication used to treat sexual dysfunction in the United States and the factors that are likely to shape the future of this market. It addresses important areas in the sexual dysfunction markets including patient potential, unmet needs in current disease treatment, besides analyzing drivers, restraints, and challenges. Competitive analysis, pipeline analysis, and revenue, price, and demand forecasts are also provided.
Greater Awareness of Disease Indications Expands User Base
New indications add to the cumulative demand within the sexual dysfunction medication market, lead to multiple treatment opportunities, and enable pharmaceutical companies to rapidly develop products that will serve several market segments, while limiting additional costs, says the analyst of this research service. Multiple treatment opportunities arise from overlapping features between diseases such as hypogonadism and erectile dysfunction and between the latter and secondary premature ejaculation, offering scope for companies to profit in a myriad ways within particular market segments such as the male sexual dysfunction market.
In addition, similarities between male and female sexual dysfunctions that can be treated with similar drug formulations provide pharmaceutical companies with an expanding patient base and doubled sales in the same class of medication. For example, Viagra that initially catered to the erectile dysfunction segment could now possibly double as treatment for females in the arousal disorder segment. Other similar market segments are the male hypogonadism and female hypoactive desire disorder segments with testosterone replacement products being developed for both groups.
Low Market Penetration Provides Scope for Growth
The highly untapped potential of the market stemming from the unmet medical needs of the patient base create lucrative opportunities for companies that can establish early market entries, notes the analyst. Despite the 43 percent of women and 31 percent of men in the United States that require treatment for sexual dysfunction, the market penetration rates are extremely low.
Although erectile dysfunction and hypogonadism are two segments that currently have drugs approved by the Food and Drug Administration (FDA), the market has not been adequately exploited. Female sexual dysfunctions that consist of four FDA-accepted indications have no approved drug as yet, resulting in greater opportunities for pharmaceutical manufacturers.
Customers who bought this item also bought
Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
Stakeholder Opinions: Female Sexual Dysfunction - Results From Datamonitors 2005 Physician Survey
Major Milestones: Female Sexual Dysfunction
Male and female sexual dysfunction: Blockbuster indication for multiple pharmacological targets
Strategic Perspectives: Female Sexual Dysfunction - Are Physicians and Patients Ready For a Female Viagra?
Womens Health Female Sexual Dysfunction
The World Market For Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry
Female Sexual Dysfunction Therapy Area Pipeline Report
Stakeholder Opinion: Erectile Dysfunction - Identifying Product Differentiation and Patient Segmentation Strategies
Handbook of Sexual and Gender Identity Disorders
European Erectile Dysfunction Therapy and Device Markets
U.S. Alzheimer's Disease Medication Markets
|
|
|
|
